Comparing the current results to its competitors, Pacira Biosciences Inc reported Revenue increase in the 2 quarter 2026 by 6.24 % year on year. The sales growth was above Pacira Biosciences Inc 's competitors' average revenue growth of 5.43 %, achieved in the same quarter.
Pacira Biosciences Inc 's Comment on Competition and Industry Peers
The pharmaceutical and medical device industries are characterized by intense competition and rapid change. Competitors include multinational pharmaceutical companies, established biotechnology firms, specialty pharmaceutical companies, generic drug manufacturers, and smaller or early-stage companies, particularly those collaborating with larger organizations. Many competitors possess greater financial resources, larger research and development teams, and more extensive marketing and manufacturing capabilities, which can facilitate faster marketing approvals and more effective product development, sales, and marketing. Specific products such as EXPAREL compete with well-established similar products and emerging biologic therapies, including stem cell and platelet-rich plasma (PRP) injections. In the cryotherapy pain management sector, competition is increasing due to growing interest in alternatives to opioids, with numerous competitors, including small and early-stage companies, entering the market with superior resources and capabilities. Pacira BioSciences, Inc. is identified as a competitor in this field.
With revenue growth of 6.24 % within Overall company, Pacira Biosciences inc achieved improvement in market share, within Overall company to approximately 0.64 %. << More on PCRX Market Share.
*Market share is calculated based on total revenue.
November 14, 2024
: This article aims to synthesize findings from recent data presented by Pacira Biosciences at the ACR Convergence annual meeting regarding the long-term safety and efficacy of their investigational product, PCRX-201, for moderate to severe osteoarthritis of the knee. It will provide an overview of the product’s clinical profile and market context based on available financial data.Osteoarthritis of the knee is a degenerative joint disease that significantly impacts the quality of life for millions worldwide. Traditional management strategies often involve pharmacological therapies, physical rehabilitation, and, in severe cases, surgical intervention. As the search for effective treatment options continues,...
September 26, 2024
In a significant advancement for the treatment of moderate to severe osteoarthritis of the knee, Pacira BioSciences, Inc. (NASDAQ: PCRX), a leader in innovative non-opioid pain management solutions, has announced the forthcoming presentation of compelling 104-week safety and efficacy data surrounding its gene therapy candidate, PCRX-201 (enekinragene inzadenovec). This groundbreaking information is set to be unveiled during the renowned American College of Rheumatology s annual meeting, ACR Convergence 2024, scheduled for November 14-19 in Washington, D.C.Osteoarthritis represents one of the most prevalent forms of arthritis globally, characterized by the degeneration of joint cartilage and underlying bone, ...
February 7, 2024
In an era marked by the opioid crisis, the need for reliable non-opioid pain management and regenerative health solutions has never been more urgent. Consequently...
Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Mallinckrodt Plc's business model revolves around acquiring and developing branded pharmaceutical products, as well as manufacturing and distributing generic and specialty pharmaceuticals. They aim to address unmet medical needs and improve patient lives through their diverse portfolio of drugs.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Sources:
Pacira Biosciences inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Pacira Biosciences inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
